The Boston Globe reported this week on current trends in genetic testing of tumors:
- Massachusetts General Hospital will be adding $2,000 per patient worth of genetic testing as part of its standard of care for cancer.
- Dana-Farber tests selected patients, including patients with certain melanomas, where doctors know those malignancies can carry abnormalities that are susceptible to certain drugs.
- Memorial Sloan-Kettering Cancer Center in New York, will start screening most patients with lung cancer within weeks.
This week has seen some scientific developments reported in tumor screening as well:
- A study in PNAS reports on an analysis of genome-wide expression and copy-number data in endometrial cancers and finds a couple of prognostically-relevant results.
- A study in the Journal of Clinical Oncology reports on the use of a 50 gene array to successfully identify four breast cancer tumor types that have been previously defined: luminal A, luminal B, HER2-enriched and basal-like.
We’ll see if the accumulation of data is sufficient to make a case for insurance coverage.
2 responses so far ↓
Trends Update — Personalized Medicine: DxS’ Latest Companion Diagnostics Deal « The Cross-Border Biotech Blog // May 31, 2009 at 1:32 pm |
[...] 31, 2009 · No Comments As personalized medicine inches toward becoming the standard of care for cancer, the question of who pays for the genotyping becomes more important. A deal announced Friday [...]
Trends Update — “Personalized Effectiveness”: Amgen Gets Prospective Data to Back KRAS-Vectibix Plan « The Cross-Border Biotech Blog // August 11, 2009 at 2:23 pm |
[...] tumor genotyping as a standard of care; [...]